Advanced Drug Delivery Strategies for Targeting Chronic Inflammatory Lung Diseases

Chapter 1. An introduction to respiratory diseases and an emerging need for efficient drug delivery systems.- Chapter 2. Inflammatory respiratory diseases: Correlation between Lung cancer and CoVid-19.- Chapter 3. Advancements in translational respiratory research using nanotechnology.- Chapter 4. Chemical moieties as advanced therapeutics for targeting respiratory disorders.- Chapter 5. Phytochemicals and their nanoformulations targeted for pulmonary diseases.- Chapter 6. Nanocarriers: an advanced and highly effective approach for targeting chronic lung diseases.- Chapter 7. Vesicular drug delivery systems in respiratory diseases.- Chapter 8. Nanoparticles in chronic respiratory diseases.- Chapter 9. Applications of nanotechnology in pulmonary disease diagnosis.- Chapter 10. Nanotechnology in pulmonary disease diagnosis.- Chapter 11. Recent trends in Nanomedicine for diagnosis and treatment of pulmonary diseases.- Chapter 12. Strategies for enhanced drug targeting to inflamed lungs: Novel perspectives.- Chapter 13. Solid-Lipid Nanocarriers (SLN's) based drug delivery for treating various pulmonary diseases.- Chapter 14. Microparticles, microspheres and microemulsions as pulmonary drug delivery systems for the treatment of respiratory diseases.- Chapter 15. Microparticles, microspheres and microemulsions in respiratory diseases.- Chapter 16. Advanced drug delivery systems targeting the immune system at cellular level in chronic respiratory diseases.- Chapter 17. Targeted Micellar Systems for Pulmonary Disease Intervention.- Chapter 18. Polymeric and inorganic nanoparticles targeting chronic respiratory diseases.- Chapter 19. Mucoadhesive drug delivery system in chronic respiratory diseases.- Chapter 20. Liposomal Drug Delivery: Therapeutic Applications in Chronic Respiratory Diseases.- Chapter 21. Biologics and vaccines for nasal and pulmonary drug delivery.- Chapter 22. Drug delivery systems for respiratory infections.- Chapter 23. Cell and Gene Therapies for

DineshKumarChellappan currently works at the International Medical University (IMU), Kuala Lumpur, Malaysia. He has more than 12 years of teaching experience in the current profession. He completed his Ph.D. in Pharmaceutical Sciences, from the Manipal University, India, in 2009. Prior to that, he did his Master's in Pharmacy from the same university. He has worked on several research projects, especially in the field of diabetes and inflammation. He has published more than 1200 publications in reputed research journals with a cumulative impact factor of >2400. He also has presented a number of papers at conferences and has received research grants, both at national and international levels, to conduct research. In addition, heis a reviewer and is on the editorial board of several research journals. His area of expertise lies in the preparation of standardized plant extracts, isolation of phytoconstituents, characterization and structural elucidation of phytoconstituents, and pharmacological research of standardized extract for its various activities. 

KavitaPabreja holds a Doctoral degree in Drug Discovery Biology from Monash Institute of Pharmaceutical Sciences, Monash University, Australia. Dr Pabreja's lecturing experience covers >5 years across national and international Universities, where she actively contributed to medical research and curriculum development. Her research experience includes >10 years of laboratory-based research focuse^21 original research and review articles in high-quality peer-reviewed journals. Currently, Dr Pabreja is utilizing her knowledge and skills in the role of Regulatory Affairs Coordinator with a leading Australian novel vaccine research company.


Md. Faiyazuddin has over 15 years of experience as an entrepreneur, academician, and researcher in the frontier areas of Pharmaceutical Sciences and Nanomedicine. Dr.